2 active not recruiting, 2 completed, 2 terminated, 1 withdrawn. 4 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Enoblituzumab: new trials by email Literature Review of Enoblituzumab trials Research Report on Enoblituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer Enoblituzumab, Standard of Care - Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 219 | 2024-02-16 | 2026-07-24 |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT538, Enoblituzumab - Cancer, Solid Tumor | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2023-04-28 | 2025-08-14 |
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer IP FT516, Enoblituzumab, IL-2 - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 3 | 2021-04-02 | 2023-04-03 |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Enoblituzumab, Retifanlimab, Tebotelimab - Head and Neck Cancer, Head and Neck Neoplasms | Phase 2 | Terminated | MacroGenics | 62 | 2021-03-17 | 2023-12-20 |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck enoblituzumab, MGA012, MGD013 - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 / Phase 3 | Withdrawn | MacroGenics | 2019-10-01 | 2022-02-08 | |
| Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Enoblituzumab - Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 33 | 2017-02-14 | 2026-08-21 |
| Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Enoblituzumab - Neuroblastoma, Rhabdomyosarcoma | Phase 1 | Completed | MacroGenics | 25 | 2016-12-01 | 2022-02-08 |
Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Desmoplastic Small Round Cell Tumor (1) · Fallopian Tube Neoplasms (1) · Laryngeal Neoplasms (1) · Neoplasms (1) · Neuroblastoma (1) · Osteosarcoma (1) · Rhabdomyosarcoma (1) · Sarcoma, Ewing (1) · Wilms Tumor (1)
MacroGenics (3) · Masonic Cancer Center, University of Minnesota (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)
United States (6) · Australia (1) · Bulgaria (1) · Hungary (1) · Poland (1) · Spain (1) · Ukraine (1)
Ashley L. Ward, MD (1) · Eugene Shenderov (1) · Eugene Shenderov, MD, PhD (1) · Melissa Geller, MD, MS (1)
P01CA111412 (2)